ACXPAcurx Pharmaceuticals Inc
$1.53
$0.00
(0.00%)
Pre-Market
EarningsAug 12
Mkt Cap$6.66M
Vol10.00
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Acurx Pharmaceuticals Announces Presentation of Results from Leiden...
PR Newswire
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update PR Newswire...
PR Newswire
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 Acurx Announces Scientific Poster Presentation of its DNA pol IIIC...
PR Newswire
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PR Newswire STATEN ISLAND, N.Y., April 29, 2026 STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire...
PR Newswire
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results...
PR Newswire
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire STATEN ISLAND...
PR Newswire
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct...
PR Newswire
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Zacks
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest ACXP News
ViewAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
PR Newswire
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Zacks
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
PR Newswire
Advertisement|Remove ads.